Reversing binding sensitivity to A147T translocator protein

Sophie V. Vo, Samuel D. Banister, Isaac Freelander, Eryn L. Werry, Tristan A. Reekie, Lars M. Ittner, Michael Kassiou*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The translocator protein (TSPO) is a target for the development of neuroinflammation imaging agents. Clinical translation of TSPO PET ligands, such as [11C]DPA-713, has been hampered by the presence of a common polymorphism (A147T TSPO), at which all second-generation TSPO ligands lose affinity. Little is known about what drives binding at A147T compared to WT TSPO. This study aimed to identify moieties in DPA-713, and related derivatives, that influence binding at A147T compared to WT TSPO. We found changes to the nitrogen position and number in the heterocyclic core influences affinity to WT and A147T to a similar degree. Hydrogen bonding groups in molecules with an indole core improve binding at A147T compared to WT, a strategy that generated compounds that possess up to ten-times greater affinity for A147T. These results should inform the future design of compounds that bind both A147T and WT TSPO for use in neuroinflammation imaging.

Original languageEnglish
Pages (from-to)511-517
Number of pages7
JournalRSC Medicinal Chemistry
Volume11
Issue number4
DOIs
Publication statusPublished - 1 Apr 2020

Fingerprint Dive into the research topics of 'Reversing binding sensitivity to A147T translocator protein'. Together they form a unique fingerprint.

  • Cite this

    Vo, S. V., Banister, S. D., Freelander, I., Werry, E. L., Reekie, T. A., Ittner, L. M., & Kassiou, M. (2020). Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 11(4), 511-517. https://doi.org/10.1039/c9md00580c